pre-IPO PHARMA

COMPANY OVERVIEW

Quanta Therapeutics, Inc. is a privately-held biopharmaceutical company focused on first-in-class direct approaches targeting the protein interactions key to oncogenic RAS activity. RAS is the most prevalent and elusive target in oncology. Quanta’s success thus far has driven by their uniquely developed platform, applying Second Harmonic Generation (SHG) optical technology to identify modulators of membrane-protein-complex conformation in real-time drug screening and yielding unparalleled sensitivity to detect change in functional states. The Quanta team has extensive drug development expertise and substantial research experience in the RAS space. Application of unique protein conformation detection technology and medicinal chemistry expertise is anticipated to yield novel small molecules as first-in-class precision medicines designed to address the resistance paradigms of targeted therapy in oncology.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.quantatx.com/


    CAREER WEBSITE

    https://www.quantatx.com/#careers


    SOCIAL MEDIA


    INVESTORS

    abbvie-ventures bvf-partners logos-capital longitude-capital sofinnova-investments surveyor vida-ventures


    PRESS RELEASES


    May 22, 2023

    Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors


    Apr 14, 2023

    Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session


    Mar 14, 2023

    Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annual AACR Meeting


    Dec 13, 2022

    Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer


    Oct 26, 2021

    Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs


    For More Press Releases


    Google Analytics Alternative